Two patients with rituximab associated low gammaglobulin levels and relapsed covid-19 infections treated with convalescent plasma
Patients with haematological malignancies are considered to be a risk group for developing severe Coronavirus disease (Covid-19). Because of the limitations of therapeutic options, the development of new treatment strategies is mandatory, such as convalescent plasma (CP). Herein we report the use of CP therapy as an off-label indication in two lymphoma patients with relapsed COVID-19 in the setting of low gammaglobulin levels because of previous rituximab chemo-immunotherapy. Both were PCR positive for SARS-CoV-2 but had an absence of antibodies to the virus more than one month later of symptoms initiation. (Source: Transf...
Source: Transfusion and Apheresis Science - February 19, 2021 Category: Hematology Authors: Irati Ormazabal V élez, Juan Induráin Bermejo, José Espinoza Pérez, Laura Imaz Aguayo, Marina Delgado Ruiz, José Antonio García-Erce Source Type: research

Facts and Challenges on Global Deployment of Vaccines for the Immunotherapy of the Evolving SARS Cov-2 variants: What a New Year, With a Fast Spreading South African and the Most Fearful Brazilian Variants, as the Unwanted Gifts, Imposing Enormous Crises to Surmount
In this What ’s Happening commentary, as a follow up up of trasci 60.1 on the “New Generation of Vaccines and Convalescent Plasma Therapy for Management of CoV-2”. I am opting to remain on the same hot topic which is of current interest to all at the international level. (Source: Transfusion and Apheresis Science)
Source: Transfusion and Apheresis Science - February 18, 2021 Category: Hematology Authors: Jerard Seghatchian Tags: Editorial Source Type: research

Changes in blood donation and utilization secondary to Covid-19 outbreak
This study was funded by Funda ção Pró-Sangue São Paulo Hemocenter (no grant number) (Source: Transfusion and Apheresis Science)
Source: Transfusion and Apheresis Science - February 17, 2021 Category: Hematology Authors: Carla L. Dinardo, Monica J. Vieira, Vanderson Rocha, Alfredo Mendrone-J únior Source Type: research

The Story of an Extraordinary Year: Challenges and Opportunities in Responding to Covid-19
Little more than a year after the first reports of a new coronavirus in Wuhan, China, the world is in the middle of a pandemic that has brought dramatic changes in societies all over the world. This is our story, as seen from the Department of Immunology and Transfusion at Oslo University Hospital (OUH). (Source: Transfusion and Apheresis Science)
Source: Transfusion and Apheresis Science - February 16, 2021 Category: Hematology Authors: Lise Sofie H. Nissen-Meyer, Arne Broch Brants æter Source Type: research

The prevalence of pre-operative anaemia and an examination of its effect on transfusion practice between sexes: a multicentre retrospective study
(Source: Transfusion and Apheresis Science)
Source: Transfusion and Apheresis Science - February 15, 2021 Category: Hematology Authors: Jennifer Kielty, David Hannon, Andrew Smith, Aine McCarthy, Gloria Avalos, Brendan Dineen, Jennifer McElwain Source Type: research

Inventory Management in Blood Supply Chain Considering Fuzzy Supply/Demand Uncertainties and Lateral Transshipment
Supply and demand uncertainties combined with very short lifetime of blood platelets has led to significant wastage of the total blood collected from the donors. Conversely, great shortage of platelets may be obtained due to the limited number of donors and emergency demands. Therefore, it is of utmost importance to develop appropriate inventory management model to simultaneously minimize both shortage and wastage along the blood supply chain. To achieve this purpose, this paper presents an Inventory Management model for Age-differentiated platelets under supply/demand Uncertainties (IMAU) for Blood Supply Chains with Late...
Source: Transfusion and Apheresis Science - February 15, 2021 Category: Hematology Authors: Mohammad Shokouhifar, Malek Mohammad Sabbaghi, Nazanin Pilevari Source Type: research

Immunotherapy for COVID-19: Evolving Treatment of Viral Infection and Associated Adverse Immunological Reactions
This review on COVID-19 vaccinotherapy enables a comparative analysis of the short-list of currently approved major vaccines. These include the Pfizer and Moderna first mRNA vaccines under FDA purview and the Oxford/AstraZeneca simian adenovirus-vectored vaccine (under UK-MHPRA guidance), all produced in record time, being safe and effective. The Pfizer and Moderna double dose vaccines have the clear edge in treatment efficacy, being in the 90% range compared to AstraZeneca in the average 70%. However, the AZ double dose vaccine has significant advantages with respect to lower cost and stability in storage. (Source: Transf...
Source: Transfusion and Apheresis Science - February 13, 2021 Category: Hematology Authors: Jeffrey S. Putter Source Type: research

Symmetrical Peripheral Gangrene in Critical Illness
Symmetrical peripheral gangrene (SPG) is a disabling complication that affects a small proportion of patients who survive critical illness. Its pathogenesis reflects profoundly disturbed procoagulant-anticoagulant balance in susceptible tissue beds secondary to circulatory shock (cardiogenic, septic). There is a characteristic SPG triad: (a) shock (hypotension, lactic acidemia, normoblastemia, multiple organ dysfunction), (b) disseminated intravascular coagulation (DIC), and (c) natural anticoagulant depletion (protein C, antithrombin). (Source: Transfusion and Apheresis Science)
Source: Transfusion and Apheresis Science - February 13, 2021 Category: Hematology Authors: Theodore E. Warkentin, Shuoyan Ning Source Type: research

Practice Patterns and Clinical Outcomes of Platelet Alloimmunization in a Comprehensive Cancer Center
Thrombocytopenia, or low platelet counts, is a common problem in the oncology population and it can be related to cancer diagnosis and treatments, as well as other etiologies [1]. As platelets are paramount to maintaining normal hemostasis, thrombocytopenia is a risk factor for bleeding in patients and sometimes necessitates platelet transfusion support. Patients with malignancy frequently require platelet transfusions during cancer treatment and are at risk of suffering platelet transfusion refractoriness (PTR). (Source: Transfusion and Apheresis Science)
Source: Transfusion and Apheresis Science - February 13, 2021 Category: Hematology Authors: Rohit V. Goswamy, Nathaniel R. Wilson, Daniel J. Tannenbaum, Fleur M. Aung, Cristhiam Mauricio Rojas Hernandez Source Type: research

First experience of the use of a generic of plerixafor in peripheral blood stem cell mobilization in multiple myeloma and lymphoma patients
(Source: Transfusion and Apheresis Science)
Source: Transfusion and Apheresis Science - February 11, 2021 Category: Hematology Authors: MA. Bekadja, B. Mansour, H. Ouldjeriouat, B. Entasoltan, S. Bouchama, L. Charef, K. Amani, N. Hakiki, F. Bouamama, S. Osmani, M. Brahimi, A. Arabi, R. Bouhass, N. Yafour. Source Type: research

People with blood disorders can be more vulnerable during COVID-19 pandemic: A Hypothesis Paper
The world has been encountered with COVID-19 pandemic since at the beginning of 2020 and the number of infected people by COVID-19 is increasing every day. Despite various studies conducted by researchers and doctors, no treatment has been developed until now, therefore self-protection and isolation are strongly recommended to stop the spread of the virus. The elderly population and people with chronic diseases such as hypertension, cardiovascular diseases, diabetes, and cancer are categorized as risk groups, however, we suggest that people with hemoglobinopathies or porphyria can be described as risk groups as well. (Sour...
Source: Transfusion and Apheresis Science - February 10, 2021 Category: Hematology Authors: Duygu Aydemir, Nuriye Nuray Ulusu Tags: Review Source Type: research

Peripheral Blood Stem Cell Grafts in Allogeneic Hematopoietic Cell Transplantation: It is Not All About the CD34+ Cell Dose
Allogeneic Hematopoietic Cell Transplantation is a curative approach in various malignant and non-malignant disorders. The majority of adult transplants in the current era are performed using mobilized stem cells, harvested from the peripheral blood by leukapheresis. Peripheral blood stem cell (PBSC) collections are designed to target a dose of stem cells that will result in safe engraftment and hematopoietic recovery; however, 99% of the cells contained in a PBSC graft are not stem cells and a growing number of studies attempt to characterize the associations between graft composition and transplant outcomes. (Source: Tra...
Source: Transfusion and Apheresis Science - February 10, 2021 Category: Hematology Authors: Ran Reshef Source Type: research

MicroRNA Expression Profiles Analysis of Apheresis Platelets Treated With Vitamin B2 and Ultraviolet-B During Storage
Whether platelet (PLT) microRNA (miRNA) profiles are affected by pathogen reduction technology (PRT) using vitamin B2 and ultraviolet-B (VB2-PRT) remains unclear. Samples from VB2-PRT-treated (experimental group, E_) and untreated (control group, C_) apheresis PLTs were taken on days 1, 3 and 5 of storage, designated as E_1, E_3, E_5, C_1, C_3 and C_5, respectively. The miRNA expression profiles were assessed by DNA Nano Ball (DNB) sequencing technology, and verified by quantitive real-time fluorescence quantitative PCR (qRT-PCR). (Source: Transfusion and Apheresis Science)
Source: Transfusion and Apheresis Science - February 8, 2021 Category: Hematology Authors: Hui Ye, Huicong Xu, Mingming Qiao, Rui Guo, Yanbo Ji, Yuan Yu, Yuanfeng Chen, Xia Gai, Honglei Li, Qun Liu, Yunlong Zhuang Source Type: research

Plerixafor combined with G-CSF for stem cell mobilization in children qualified for autologous transplantation- single center experience
Failure of autologous peripheral blood CD34+ stem cells collection can adversely affect the treatment modality for patients with hematological and nonhematological malignant diseases where high dose chemotherapy followed by hematopoietic stem cell transplantation has become part of their treatment. Plerixafor in conjunction with G-CSF is approved for clinical use as a mobilization agent. The clinical efficacy of Plerixafor in CD34+ cells collection was analyzed in our institution. A total of 13 patients aged 1 to 15,5 years received Plerixafor in combination with G-CSF: 7 with neuroblastoma, 2 with Ewing ’s sarcoma a...
Source: Transfusion and Apheresis Science - February 5, 2021 Category: Hematology Authors: Iwona Malinowska, Michal Romiszewski, Katarzyna Smalisz, Anna Stelmaszczyk - Emmel, Barbara Nasilowska - Adamska, Malgorzata Krol, Elzbieta Urbanowska, Agnieszka Brozyna, Bozenna Baginska - Dembowska Source Type: research

Genotyping of RHD c.1227G > A allele by melting curve analysis
DEL is the weakest known D-positive phenotype and is detectable only by adsorption and elution tests. RHD c.1227G>A is an important marker for DEL phenotype in East Asians. The aim of this study was to develop a method for RHD c.1227G>A genotyping by single-tube PCR with melting curve analysis. (Source: Transfusion and Apheresis Science)
Source: Transfusion and Apheresis Science - February 5, 2021 Category: Hematology Authors: Ni Wang, Yaxin Fan, Shihang Zhou, Linnan Shao, Yuexin Xia, Ming Liu Source Type: research

Recurrent Hyperhemolytic Transfusion Reaction in Myelodysplastic Syndrome- A Case Based Approach
We present here a case report of a 27  year old female, with myelodysplatic syndrome suspected to have recurrent hyperhemolytic transfusion reactions (HHTR). Patient was transfusion dependent for ten years and was transfused with leukodepleted and irradiated Packed Red Blood Cells (PRBC). She presented with signs and symptoms of acute intravascular hemolysis, deranged coagulation profile with post transfusion Hb lower than baseline. Post transfusion workup was uneventful. She was managed conservatively with fluid support and methylprednisolone initially. (Source: Transfusion and Apheresis Science)
Source: Transfusion and Apheresis Science - February 4, 2021 Category: Hematology Authors: Merline Augustine, Mohandoss Murugesan, Chandran K. Nair, Vineetha Raghavan, Sangeetha K. Nayanar Source Type: research

Convalescent plasma therapy for severe Covid-19 in patients with hematological malignancies
Data on convalescent plasma therapy (CPT) in patients of hematological malignancies with severe Covid-19 is scarce. (Source: Transfusion and Apheresis Science)
Source: Transfusion and Apheresis Science - February 3, 2021 Category: Hematology Authors: Preethi Jeyaraman, Narendra Agrawal, Rahul Bhargava, Divya Bansal, Rayaz Ahmed, Dinesh Bhurani, Sachin Bansal, Neha Rastogi, Pronamee Bora, Rahul Naithani, Delhi Hematology Group Source Type: research

Transfusion Practice Blind Spot in Para-Bombay: A Case Report
We report a case of a 59-year-old-man presented with symptomatic anaemia secondary to upper gastrointestinal bleed with haemoglobin level of 68  g/L who required two units of packed red blood cells. He was previously grouped as O Rh D positive and had a history of uneventful multiple blood transfusions. His latest pre-transfusion investigations showed ABO discrepancy between forward and reverse blood grouping, pan-agglutination in both an tibody screening and identification with negative direct Coombs test and autocontrol. (Source: Transfusion and Apheresis Science)
Source: Transfusion and Apheresis Science - February 3, 2021 Category: Hematology Authors: Mohd Redzuan Abdullah, Afif Alam Faizli, Siti Salmah Noordin, Lee Chin Jian, Nor Hafizah Ahmad Source Type: research

The effect of serum lipid levels on peripheral blood hematopoietic stem cell levels
There are limited numbers of available retrospective studies on various hematological diseases treated with stem cell mobilization therapy. In the present study, we aimed to demonstrate the effects of serum lipid levels on peripheral blood CD34+ (PBCD34+) cell counts as well as the changes in serum lipid levels during stem cell mobilization process. (Source: Transfusion and Apheresis Science)
Source: Transfusion and Apheresis Science - February 3, 2021 Category: Hematology Authors: Ilgin Yildirim Simsir, Ayhan Donmez, Ceyda Kabaroglu, Irfan Yavasoglu, Gunes Basol, Ay şe Gungor, Melda Comert Ozkan, Fusun Saygili, Zahit Bolaman, Murat Tombuloglu Source Type: research

Blood donation and heavy metal poisoning in developing nations: any link?
Long term health effects of heavy metal exposure from both occupational and environmental settings involve multi-organ toxicities including but not limited to disturbances of neurological, cognitive, and metabolic processes, immune system dysregulation, carcinogenesis and sometimes permanent disabilities. Humans are exposed to toxic metals through various sources and routes of entry. The risk of heavy metal poisoning from donor blood has been the subject of many scientific investigations. In this review we highlight how the access to a safe and adequate blood transfusion with minimal risk of toxic metals to recipients is a...
Source: Transfusion and Apheresis Science - January 28, 2021 Category: Hematology Authors: Samuel J. Offor, Chinna N. Orish, Eze Eze Chidi, Chiara Frazzoli, Orish E. Orisakwe Tags: Review Source Type: research

The Impact of Blood Donation on Blood Counts and Ferritin Levels: A Multi-Center Study from the Eastern Mediterranean Region
In this study, we aimed to assess the impact of frequent whole blood donation on hematological parameters. Whole blood donors were enrolled from four blood banks located in Saudi Arabia, United Arab Emirates (UAE), Libya and Oman, between 2016 and 2017. SPSS version 21.0 was used to generate descriptive and inferential statistics. A total number of 3,096 blood donors were screened (males 93.8%, females; 6.2%), with a mean donor age of 35.29  ± 9.31 years. (Source: Transfusion and Apheresis Science)
Source: Transfusion and Apheresis Science - January 27, 2021 Category: Hematology Authors: Salwa Hindawi, Maha Badawi, Deema Hussein, Arwa Z. Al-Riyami, Nureddin A. Daghman, Nawal Ibrahim Rafie, Najat Mohmod Belgasm, Eiman Al Zaabi, Naima Oumeziane Source Type: research

Covid-19 neutralizing antibody-based therapies in humoral immune deficiencies: a narrative review
The outbreak of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), generated an unprecedented global health and social emergency. Despite many efforts from clinicians to develop effective anti-COVID-19 treatment protocols, no specific therapy is currently available. Among anti-viral agents, convalescent plasma (CP) from recovered patients is the object of intense research following the first positive reports in severe COVID-19 patients. Passive immunotherapy the rationale to provide higher benefits in COVID-19 patients with humoral immune deficiencies, such as those...
Source: Transfusion and Apheresis Science - January 26, 2021 Category: Hematology Authors: Daniele Focosi, Massimo Franchini Tags: Review Source Type: research

Effects of ultrasound guided leukocyte-rich platelet-rich plasma (LR-PRP) injection in patients with pes anserinus tendinobursitis
To demonstrate the efficacy and safety of ultrasound guided leukocyte-rich platelet-rich plasma (LR-PRP) injection in patients with pes anserinus tendinobursitis(PATB). (Source: Transfusion and Apheresis Science)
Source: Transfusion and Apheresis Science - January 25, 2021 Category: Hematology Authors: Çağlar Karabaş, Havva Talay Çaliş, Ulaş Serkan Topaloğlu, Çiğdem Karakükçü Source Type: research

Optimization of repeat plerixafor dosing for autologous peripheral blood stem-cell collection
Peripheral CD34+ cells may be mobilized using filgrastim alone or in combination with chemotherapy. The addition of plerixafor can be efficacious, though guidelines for repeat dosing are lacking. (Source: Transfusion and Apheresis Science)
Source: Transfusion and Apheresis Science - January 25, 2021 Category: Hematology Authors: Gaurav K. Gupta, Sarah Perreault, Stuart E. Seropian, Christopher A. Tormey, Jeanne E. Hendrickson Source Type: research

Iatrogenic anaemia and transfusion thresholds in ICU patients with COVID-19 disease at a tertiary care hospital
Patients with severe COVID-19 disease frequently develop anaemia as the result of multiple mechanisms and often receive transfusions. The aims of this study were to assess the impact of repeated blood samplings on patients ’ anaemic state using standard-volume tubes, in comparison with the hypothetical use of low-volume tubes and to evaluate the transfusion policy adopted. (Source: Transfusion and Apheresis Science)
Source: Transfusion and Apheresis Science - January 22, 2021 Category: Hematology Authors: Ivo Beverina, Erika Borotto, Chiara Novelli, Danilo Radrizzani, Bruno Brando Source Type: research

Guest Editor ’s Bio: Dr. Yvette Tanhehco and Dr. Joseph Schwartz
Dr. Yvette C. Tanhehco is an Assistant Professor of Pathology and Cell Biology at Columbia University Irving Medical Center (CUIMC) and the Director of the Cellular Therapy Laboratory and Assistant Director of Transfusion Medicine at NewYork-Presbyterian Hospital/CUIMC. (Source: Transfusion and Apheresis Science)
Source: Transfusion and Apheresis Science - January 13, 2021 Category: Hematology Source Type: research

A Look-Back at Convalescent Plasma to Treat COVID-19
The transfer of immunity from a protected to an infected host dates back to the end of the XIXth century, on both experimental and clinical grounds. Perhaps the pioneer large scale experience has achieved during the so-called Spanish flu, a disease which killed almost twice to five times more people (depending on the model used) than the preceeding WWI. After that first experience, nearly all severe or serious infectious outbreaks involving a viral pathogen have been considered eligible for convalescent plasma collection from donors who have recovered from the infection [reviewed in: [1,2]]; this therapy, however, was acco...
Source: Transfusion and Apheresis Science - January 11, 2021 Category: Hematology Authors: Olivier Garraud, Karine Lacombe, Pierre Tiberghien Source Type: research

New generation of vaccines and convalescent plasma therapy for management of CoV-2: Perspectives from the UK and potential deployment in the current global pandemic
Coronavirus COVID-19 (official nomenclature SARS-CoV-2), has, since March 2020 when the WHO announced its pandemic nature, created major challenges in the world, causing a public health crises with severe economic consequences. A crucial element of this highly contagious virus is its capability to propagate exponentially into susceptible hosts, often causing severe inflammatory thrombotic microcirculatory events leading to multiorgan dysfunction and emergency hospitalisations, causing chaos in healthcare systems. (Source: Transfusion and Apheresis Science)
Source: Transfusion and Apheresis Science - January 11, 2021 Category: Hematology Authors: Jerard Seghatchian Tags: Editorial Source Type: research

Addition of plerixafor to G-CSF in poor mobilizing healthy related donors overcame mobilization failure: an observational case series on behalf of the Grupo Espa ñol de Trasplante Hematopoyético (GETH)
Plerixafor (Mozobil, Sanofi) is approved for using in patients with lymphoma and multiple myeloma when steady-state mobilization strategies fail. Although off-label use of plerixafor in healthy related donors (HRD) is known, limited data is available and no recommendations exist to guide its use in this setting. With the aim of collecting data from HRDs who received plerixafor in our country, we designed an observational case series study within the Spanish Group of Hematopoietic Transplant and Cell Therapy (GETH). (Source: Transfusion and Apheresis Science)
Source: Transfusion and Apheresis Science - January 11, 2021 Category: Hematology Authors: Joan Cid, Silvia Monsalvo, Carlos Castillo, Cristina Pascual, Gemma Moreno-Jim énez, Miriam López-Parra, Concepción Andón, Luisa Guerra, Albert Esquirol, Isabel Sánchez-Ortega, Sandra Ortega, Saioa Zalba, Carmen Martínez, Montserrat Rovira, Pedro Ma Source Type: research

Cellular and Gene Therapy for the Treatment of Hematologic Diseases and Solid Tumors: The Dawn of a New Era
Cellular therapies for the treatment of hematologic diseases have been around for decades but it has become front and center in the last few years with the Food and Drug Administration (FDA) approval of Kymriah (tisagenlecleucel), a CD-19-directed chimeric antigen receptor-T cell (CAR-T cell), for the treatment of acute lymphoblastic leukemia in 2017, the first FDA approved gene therapy in the United States. It was subsequently approved for diffuse large B-cell lymphoma as well. This historic event ushered in a new approach to treat malignancies and other life-threatening diseases. (Source: Transfusion and Apheresis Science)
Source: Transfusion and Apheresis Science - January 11, 2021 Category: Hematology Authors: Yvette Co Tanhehco, Joseph Schwartz Source Type: research

Mesenchymal Stromal Cells: Getting Ready for Clinical Primetime
Mesenchymal stromal cells (MSC) are multipotent precursor cells that can be derived from a variety of tissue sources, with a working definition based on immunophenotyping and cell differentiation capacity. Despite historical roots in the field of tissue engineering, they have generated great interest as cell therapies for their immune regulatory function, which has led to numerous clinical trials for a range of inflammatory and autoimmune conditions. Importantly, due to the lack of traditional MHC expression and their expression of other immune regulatory proteins, they can be used from third party donors without generatin...
Source: Transfusion and Apheresis Science - January 11, 2021 Category: Hematology Authors: Holly Wobma, Prakash Satwani Source Type: research

New generation of vaccines and convalescent plasma therapy for management of CoV-2: Perspectives from the UK and potential deployment in the current global pandemic
Coronavirus COVID-19 (official nomenclature SARS-CoV-2), has, since March 2020 when the WHO announced its pandemic nature, created major challenges in the world, causing a public health crises with severe economic consequences. A crucial element of this highly contagious virus is its capability to propagate exponentially into susceptible hosts, often causing severe inflammatory thrombotic microcirculatory events leading to multiorgan dysfunction and emergency hospitalisations, causing chaos in healthcare systems. (Source: Transfusion and Apheresis Science)
Source: Transfusion and Apheresis Science - January 11, 2021 Category: Hematology Authors: Jerard Seghatchian Source Type: research

Establishment of A Cell Processing Laboratory to Support Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor (CAR)-T Cell Therapy
Cell processing laboratories are an important part of cancer treatment centers. Cell processing laboratories began by supporting hematopoietic stem cell (HSC) transplantation programs. These laboratories adapted closed bag systems, centrifuges, sterile connecting devices and other equipment used in transfusion services/blood banks to remove red blood cells and plasma from marrow and peripheral blood stem cells products. The success of cellular cancer immunotherapies such as Chimeric Antigen Receptor (CAR) T-cells has increased the importance of cell processing laboratories. (Source: Transfusion and Apheresis Science)
Source: Transfusion and Apheresis Science - January 11, 2021 Category: Hematology Authors: Somnath Mukherjee, Opal Reddy, Sandhya Panch, David Stroncek Source Type: research

Role of anti-allergic agents on attenuating transfusion reactions in adults: A systematic review and meta-analysis
Anti-allergic agents (e.g. dexamethasone, chlorpheniramine or promethazine) are commonly administered to patients prior to blood product transfusions. However, the use of these agents is largely experience-based instead of evidence-based. This meta-analysis aimed to explore the evidence behind using anti-allergic agents to attenuate transfusion reactions. (Source: Transfusion and Apheresis Science)
Source: Transfusion and Apheresis Science - January 10, 2021 Category: Hematology Authors: Shiyuan Yu, Yanxia Gao, Joseph Harold Walline, Xin Lu, Lina Zhao, Yi Li Source Type: research

Cellular Therapy for the Treatment of Solid Tumors
Adoptive cellular therapy (ACT) is a form of cancer immunotherapy in which lymphocytes are removed from patient blood or tumor samples, expanded and/or genetically modified to improve tumor-fighting capabilities, and infused back into the patient. The main forms of ACT include tumor infiltrating lymphocytes (TILs), engineered T cell receptor (TCR) T cells, and chimeric antigen receptor (CAR) T cells. While ACT has had success in hematological malignancies, particularly in B cell lymphomas targeted with CAR T cells, these favorable outcomes have yet to be replicated in solid tumors. (Source: Transfusion and Apheresis Science)
Source: Transfusion and Apheresis Science - January 10, 2021 Category: Hematology Authors: Joseph M. Grimes, Richard D. Carvajal, Pawel Muranski Source Type: research

Allogenic Hematopoietic Stem Cell Transplantation in Sickle Cell Disease
Sickle cell disease (SCD) is one of the most common monogenic disorders worldwide and affects approximately 100,000 people in the United States alone. SCD can cause numerous complications, including anemia, pain, stroke, and organ failure, which can lead to death. Although there are a few disease-modifying treatments available to patients with SCD, the only current curative option is a hematopoietic stem cell transplant (HSCT). In this review, we will discuss the different approaches to allogeneic HSCT in the treatment of SCD and the outcomes of these approaches. (Source: Transfusion and Apheresis Science)
Source: Transfusion and Apheresis Science - January 10, 2021 Category: Hematology Authors: Dana K. Furstenau, John F. Tisdale Source Type: research

Parameters affecting successful stem cell collections for genetic therapies in Sickle Cell Disease
Emerging cellular therapies require the collection of peripheral blood hematopoietic stem cells (HSC) by apheresis for in vitro manipulation to accomplish gene addition or gene editing. These therapies require relatively large numbers of HSCs within a short time frame to generate an efficacious therapeutic product. This review focuses on the principal factors that affect collection outcomes, especially relevant to gene therapy for sickle cell disease. (Source: Transfusion and Apheresis Science)
Source: Transfusion and Apheresis Science - January 10, 2021 Category: Hematology Authors: David G. Justus, John P. Manis Source Type: research

CRISPR/Cas9 Gene Editing for Curing Sickle Cell Disease
Sickle cell disease (SCD) is the most common monogenic blood disorder marked by severe pain, end-organ damage, and early mortality. Treatment options for SCD remain very limited. There are only three FDA approved drugs to reduce acute complications. The only curative therapy for SCD is hematopoietic stem cell transplantation, typically from a matched, related donor. Ex vivo engineering of autologous hematopoietic stem and progenitor cells followed by transplantation of genetically modified cells potentially provides a permanent cure applicable to all patients regardless of the availability of suitable donors and graft-vs-h...
Source: Transfusion and Apheresis Science - January 10, 2021 Category: Hematology Authors: So Hyun Park, Gang Bao Source Type: research

Gene Therapy for Hemoglobinopathies
Beta hemoglobinopathies such as sickle cell disease (SCD) and β-thalassemia (BT) are the most common monogenic diseases worldwide. Both diseases are associated with significant morbidity and mortality. Because patients require lifelong follow-up and care, it also poses a serious burden in health services. Blood transfusions and/or drug therapy ameliorate the signs and symptoms of the disorders but are not curative. Allogeneic hematopoietic cell transplantation (HCT) is currently the only cure but it has several limitations including the paucity of human leukocyte antigen-matched related donors and a high risk of adver...
Source: Transfusion and Apheresis Science - January 10, 2021 Category: Hematology Authors: Yvette C. Tanhehco Source Type: research

Clinical Development of Natural Killer Cells Expressing Chimeric Antigen Receptors
Both natural killer (NK) cells and T cells demonstrate potent antitumor responses in many settings. NK cells, unlike T cells, are not the primary mediators of graft-versus-host (GVHD) disease. Redirection of T cells with chimeric antigen receptors (CAR) has helped to overcome tumor escape from endogenous T cells. NK cells expressing CARs are a promising new therapy to treat malignancy. Clinical biomanufacturing of CAR NK cells can begin with NK cells derived from many different sources including adult peripheral blood-derived NK cells, cord blood-derived NK cells, cell line-derived NK cells, or stem cell-derived NK cells. ...
Source: Transfusion and Apheresis Science - January 10, 2021 Category: Hematology Authors: Ryan Golden, Andrew D. Fesnak Source Type: research

Two cases of brand-specific albumin sensitivity in patients receiving regular therapeutic plasma exchange
Therapeutic plasma exchange (PLEX) involves the removal of detrimental substances, commonly pathogenic antibodies or toxins, from a patient ’s blood by exchanging their plasma with a replacement fluid. While a variety of replacement fluids are available, human albumin (4-5%) is the most commonly used, as it is widely available, easily stored, and generally well tolerated. Despite its excellent safety profile, adverse reactions to albu min are well documented, ranging in severity from mild allergic symptoms to severe anaphylaxis. (Source: Transfusion and Apheresis Science)
Source: Transfusion and Apheresis Science - January 2, 2021 Category: Hematology Authors: Kai J. Rogers, Annette J. Schlueter Source Type: research

Analysis of blood donors ’ characteristics and deferrals related to COVID-19 in Iran
Coronavirus disease 2019, called COVID-19, is caused by SARS-CoV2 that was firstly reported in Wuhan, China in December 31, 2019 [1]. SARS-CoV-2 has a non-segmented, single-stranded RNA of animal origin and is closely related genetically to the Severe Acute Respiratory Syndrome Coronavirus-1 (SARS-CoV-1) virus and more distantly related to Middle East Respiratory Syndrome Coronavirus (MERS-CoV) [2]. The disease has affected 213 countries and territories around the world which has an estimated average of 2138 laboratory-confirmed patients and 84 deaths per one million populations [3]. (Source: Transfusion and Apheresis Science)
Source: Transfusion and Apheresis Science - January 2, 2021 Category: Hematology Authors: Mohammad Hessam Rafiee, Sedigheh Amini Kafiabad, Mahtab Maghsudlu Source Type: research

Long-term Results of Allogeneic Peripheral Blood Hematopoietic Stem Cell Transplantation For Severe Aplastic Anemia
Aplastic anemia (AA) is a life-threatening disorder and may be associated with significant morbidity and mortality Currently, the first treatment option is allogeneic hematopoietic stem cell transplant (allo-HSCT) for patients younger than 40 years. Bone marrow is recommended as the stem cell source due to less graft versus host disease (GVHD) risk and better outcomes than peripheral blood (PB)-derived stem cell.. The aim of this study is to share the data of AA patients who have underwent PB-derived allo-HSCT in our bone marrow transplantation center. (Source: Transfusion and Apheresis Science)
Source: Transfusion and Apheresis Science - January 2, 2021 Category: Hematology Authors: Elifcan Aladag, Hakan Goker, Haluk Demiroglu, Salih Aksu, Nilgun Sayinalp, Ibrahim Celalettin Haznedaroglu, Osman Ilhami Ozcebe, Yahya Buyukasik Source Type: research

WHOLE BLOOD DERIVED COVID CONVALESCENT PLASMA: An Economical option among Developing Countries
(Source: Transfusion and Apheresis Science)
Source: Transfusion and Apheresis Science - January 1, 2021 Category: Hematology Authors: Ushasree Ravula, Srinivasa Rao Chunchu, Vikram Kumar Gente Tags: Letter to the Editor Source Type: research

Long-term plasmapheresis therapy in the management of focal segmental glomerulosclerosis recurrence after kidney transplantation
The recurrence of primary focal segmental glomerulosclerosis (FSGS) after kidney transplantation (KT) appears in 30% of the recipients. Sometimes it can cause the loss of the allograft. Although many treatments for this condition have been reported, 20%-40% of the affected patients are refractory or presents frequents relapses. In this paper we describe the evolution of three recipients treated with long-term plasmapheresis therapy after a recurrence of FSGS with a bad or incomplete response to other treatments. (Source: Transfusion and Apheresis Science)
Source: Transfusion and Apheresis Science - January 1, 2021 Category: Hematology Authors: Gonzalo Ramirez-Guerrero, Angel M Sevillano Prieto, Fernando Jara-Vilugr ón, Natalia Polanco Fernandez, Esther Gonzalez Monte, Ana Henandez Vicente, Lucia C Rodriguez Gayo, Manuel Praga Terente, Amado Andrés Belmonte Source Type: research

Young haploidentical donor versus fully matched elderly donor: an observational study on patients aged 50 years or older underwent hematopoietic progenitor cells transplantation
The first publication of the experimental study by Nobel laureate Edward Donnal Thomas and his group on hematopoietic progenitor cell transplantation (HPCT) was in 1957 [1]. Since then, HPCT has become a well-established treatment for a wide range of diseases including leukemias, lymphomas, immunodeficiencies and metabolic diseases. (Source: Transfusion and Apheresis Science)
Source: Transfusion and Apheresis Science - December 29, 2020 Category: Hematology Authors: Aline Miranda de Souza, Nelson Hamerschlak, Jos é Mauro Kutner Source Type: research

Evaluation of bleeding symptoms and laboratory parameters related to bleeding in sisters of patients with hemophilia A and B
Our purpose was to determine the bleeding risk of obligate and potential carriers, highlight the prophylactic applications before interventions for families and physicians. (Source: Transfusion and Apheresis Science)
Source: Transfusion and Apheresis Science - December 29, 2020 Category: Hematology Authors: Nadiye Akdeniz, Abdullah Karaku ş, İsmail Yıldız, Mehmet Orhan Ayyıldız Source Type: research

The use of convalescent plasma for pediatric patients with sars-cov-2: a systematic literature review
(Source: Transfusion and Apheresis Science)
Source: Transfusion and Apheresis Science - December 22, 2020 Category: Hematology Authors: Marco Zaffanello, Giorgio Piacentini, Luana Nosetti, Massimo Franchini Tags: Review Source Type: research

Platelet supernatant with longer storage inhibits tumor cell growth
(Source: Transfusion and Apheresis Science)
Source: Transfusion and Apheresis Science - December 21, 2020 Category: Hematology Authors: Fei Pu, Xiaofei Li, Shufang Wang, Yuanshuai Huang, Deqing Wang Source Type: research